From Congress to Clinic: A Post-JSMO Update on Novel Antibody–Drug Conjugates and Other Agents Targeting HER3 in NSCLC

Watch a CME-certified webcast and download the slides from a live, expert-led webinar to learn about new agents targeting HER3 for the treatment of non-small-cell lung cancer, including review of recent data reported at JSMO 2023.

Share

Program Content

Activities

Targeting HER3 in NSCLC
Therapeutic Relevance of HER3 in EGFR TKI-Resistant NSCLC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 03, 2023

HER3 Agents in NSCLC
Current Investigational Treatments Targeting HER3 in EGFR-Positive Post-TKI NSCLC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 03, 2023

Activities

HER3 NSCLC Update
From Congress to Clinic: A Post-JSMO Update on Novel Antibody–Drug Conjugates and Other Agents Targeting HER3 in NSCLC
Video
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2023

Expires: June 04, 2024

Activities

FAQs: Targeting HER3 in NSCLC
FAQs: Novel Antibody–Drug Conjugates and Other Agents Targeting HER3 in NSCLC
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: May 25, 2023

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from

Daiichi Sankyo, Inc.